- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Fr | OS Therapies Submits Request For RMAT Designation For OST-HER2 | 1 | RTTNews | ||
| Fr | OS Therapies seeks FDA regenerative therapy tag for cancer drug | 1 | Investing.com | ||
| 23.05. | OS Therapies Inc - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 16.05. | OS Therapies GAAP EPS of -$0.18 misses by $0.11 | 2 | Seeking Alpha | ||
| 16.05. | OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment | 1 | RTTNews | ||
| 07.05. | OS Therapies secures patent for cancer immunotherapy tech | 1 | Investing.com | ||
| 07.05. | OS Therapies sichert Patent für Krebsimmuntherapie-Technologie | - | Investing.com Deutsch | ||
| 10.04. | OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans | 272 | Newsfile | Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor,... ► Artikel lesen | |
| 09.04. | OS Therapies Inc - 8-K, Current Report | 5 | SEC Filings | ||
| 09.04. | OS Therapies übernimmt Immuntherapie-Vermögenswerte von Advaxis | 1 | Investing.com Deutsch | ||
| 09.04. | OS Therapies acquires Advaxis Immunotherapies assets | 1 | Investing.com | ||
| 31.03. | OS Therapies Inc - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | OS Therapies macht Fortschritte mit OST-HER2 für Osteosarkom | 1 | Investing.com Deutsch | ||
| 31.03. | OS Therapies advances OST-HER2 for osteosarcoma | 3 | Investing.com | ||
| 11.03. | OS Therapies, Inc.: OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma | 296 | Business Wire | OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific... ► Artikel lesen | |
| 28.02. | Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 371 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the... ► Artikel lesen | |
| 24.02. | OS Therapies sets up subsidiary to seek ADC joint ventures with US, China peers | 2 | FierceBiotech | ||
| 24.02. | OS Therapies gründet Tochtergesellschaft für Fortschritte bei Krebsmedikamenten | 1 | Investing.com Deutsch | ||
| 24.02. | OS Therapies creates subsidiary for cancer drug advances | 1 | Investing.com | ||
| 14.02. | Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer | 2 | Benzinga.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 36,800 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
| IMMUNIC | 0,698 | +1,16 % | EQS-News: Immunic AG: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,960 | +20,33 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio | - Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 12,790 | +7,30 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| PROTALIX BIOTHERAPEUTICS | 1,360 | -2,16 % | Protalix BioTherapeutics Inc. Q1 Loss Narrows | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares... ► Artikel lesen | |
| SCILEX | 6,370 | -1,55 % | Scilex announces dosing guide for gout medication GLOPERBA | ||
| MEIRAGTX | 4,700 | +0,43 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| INVIVYD | 0,985 | +6,46 % | Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, ... | CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 0,756 | -1,72 % | Lucid Capital Markets initiates Buy rating on Unicycive stock | ||
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release |
OS THERAPIES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,660 Euro und damit +3,75 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.